Helixgate https://validator.w3.org/feed/docs/rss2.html STAT+: Pharmalittle: We’re reading about a Regeneron rare disease drug, an Ultragenyx gene therapy, and more Home Helixgate AI & Biotech Collaboration Series + Helixgate Industry Nights DC judge rejects Merck’s IRA case more than three years after it was filed Safety concerns spur FDA to again halt testing of Regenxbio gene therapy FDA extends review of Capricor cell therapy; Pain drug startup to go public Capricor’s Duchenne therapy has new life after FDA grants 3-month extension Rznomics Joins Lilly Gateway Labs to Quicken RNA Therapeutic Candidate Discovery and Development Cellares, a cell therapy manufacturing specialist, to lay off 100 employees STAT+: Lady Gaga and her fiancé launch a biotech startup REGENXBIO’s Hunter syndrome gene therapy hit by FDA hold, stymieing resubmission plans STAT+: Pharmalittle: We’re reading about Medicaid obesity-drug coverage, a Regenxbio gene therapy, and more Roche bets up to $2.3B in Hanmi pact for next-gen weight loss drug FDA plans to regulate generative AI Kennedy questions vaccination guidelines following Trump’s order to break up MMR Boehringer Ingelheim suspends early study for pill candidate after ‘safety event’ Pharma marketers need a share-of-answer strategy before AI spend StockWatch: Merck/Moderna Cancer Vaccine Gives a Shot in the Arm to Sequencing Companies, Too A hidden “on switch” in human DNA has finally been decoded Queen bees have a disturbing way to survive pesticides Opinion: Medicine stopped shaking hands. We should start again Americans bought 12% less soda under new SNAP restrictions, study says Capricor, Replimune reviews signal FDA’s return to reliability but every application will stand alone Five-Year Brain Organoids Reveal New Insights Into Human Development Capricor investor calls for change as company awaits decision on Duchenne candidate STAT+: HHS document offers new clues to Kennedy’s vaccine plans Lab-Grown Neocortex Models Mimic Early Brain Organization From Models to Agents: The Next Phase of AI Adoption in Molecular Discovery Lawmakers urge FDA to enact new China policies after 3 gene therapy deaths Roche pours $750M into Oregon manufacturing plant as obesity push expands AI Identifies Pre-existing Antimicrobial Antibody Profile That May Predict Immune Response to Vaccination Scientists Analyze 267 Receptors That Control Protein Fate in Rare Diseases Regeneron to challenge Ipsen as FDA clears bone disease drug Cancer vaccine win restores Wall Street’s faith in Moderna Scribe’s early-stage IPO standout defies biotech’s derisking trend STAT+: Pharmalittle: We’re reading about a big Roche investment in the U.S., estrogen patch shortages, and more STAT+: How a Trump loyalist got the FDA nomination Werewolf and Ambros to tie the knot in $150M rare disease deal Shareholder pressures Capricor; Lilly dives deeper into vaccines This week in Drug Discovery (17-21 August 2026)  Novo Nordisk starts trialing lower maintenance doses of oral Wegovy How cost and perception could reshape the GLP-1 market Werewolf transforms into Ambros via reverse merger to support phase 3 push for rare disease drug Opinion: Lil Nas X’s bipolar diagnosis and the paradox of treatment Focal therapy for localized prostate cancer has divided physicians. Will new data change minds? STAT+: FDA approves Ultragenyx gene therapy STAT+: Up and down the ladder: The latest comings and goings DDII Digital Forum: Resilience, smarter labs, therapeutics, and capital flows “One-in-a-million” sea creature fossil preserves soft tissue for 450 million years Bonsai reconstructs tree representations for distortion-free visualization and exploration of high-dimensional data